Screener
Kura Oncology KURA SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating Expenses | ||
| Cost of product sales | 262 | — |
| Research and development | 65,263 | 55,973 |
| Selling, general and administrative | 31,555 | 22,835 |
| Total operating expenses | 97,080 | 78,808 |
| Loss from operations | (78,815) | (64,700) |
| Other Income (Expense) | ||
| Interest and other income, net | 5,826 | 7,879 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's SG&A?
- Kura Oncology (KURA) reported SG&A of $31.56M in Q1 2026.
- How has Kura Oncology's SG&A changed year-over-year?
- Kura Oncology's SG&A increased by 38.2% year-over-year, from $22.84M to $31.56M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Kura Oncology's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude